Allergan Aesthetics, part of AbbVie, has secured US FDA approval for its injectable to reduce the appearance of neck lines in adults over 21, in a first-of-its-kind indication for the product line.
The newly approved treatment, SKINVIVE by JUVÉDERM, is now the first and only hyaluronic acid injectable cleared specifically for improving neck appearance by reducing wrinkles and helping skin retain natural moisture.
Neck lines—often linked to aging, sun exposure, weight changes, and so-called “tech-neck” from prolonged device use—are among the most common aesthetic concerns in the lower face and neck area. SKINVIVE aims to address these by improving hydration, softness, and smoothness in the skin, with results lasting up to six months under optimal treatment conditions.
The treatment is administered through an ultrafine needle or cannula and is designed to be minimally invasive with little to no downtime. It also contains lidocaine to help reduce discomfort during the procedure.
“The approval of SKINVIVE by JUVÉDERM for horizontal neck wrinkles reflects Allergan Aesthetics' commitment to developing science-driven innovations that address meaningful unmet aesthetic needs,” said Darin Messina, senior vice president, aesthetics R&D at AbbVie.
“This approval expands our portfolio of lower face and neck treatment options and gives patients and aesthetic providers a first-of-its-kind treatment option for improving neck skin quality and reducing the appearance of neck lines.”
In clinical trials, the treatment showed measurable improvements, with 74.8% of participants achieving at least a one-point improvement on the Allergan Transverse Neck Lines Scale one month after treatment. At six months, 66% maintained that level of improvement.
The study also reported that most participants experienced only mild side effects such as redness, swelling, bruising, tenderness, and temporary skin changes at injection sites. These effects generally resolved within two weeks and did not require treatment in most cases. Severe adverse events occurred in fewer than 5% of participants.
_256_275.jpeg)
.jpeg)
